Valeant Pharmaceuticals International Valeant Pharmaceuticals International (NYSE: VRX) is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. Through its global infrastructure, Valeant develops and commercializes important treatments for patients worldwide. Valeant has made rapid strides since a new management team was appointed four years ago with a strategic vision and renewed focus on its specialty pharmaceuticals business. The company has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations. In 2006, Valeant total revenues were $907 million (USD), including product sales of $826 million (USD) that were generated through 370 products and more than 2,200 SKUs. Based in Aliso Viejo, California, Valeant employs 3,500 people globally. Valeant Canada Limited Valeant Canada is a specialty pharmaceutical company and is a subsidiary of Valeant Pharmaceuticals International. Valeant Canada manufactures and markets pharmaceuticals products, primarily in the areas of Neurology, Psychiatry, Pain Management and Dermatology. In 2006, Valeant Canada total revenues were $41.8 million (USD) that were generated by 39 products and more than 100 SKUs. Based in Montreal, Quebec, Valeant Canada employs 150 people. IMS Health (Canada) ranked Valeant Canada as the third (3rd) fastest growing brand manufacturers by total ethical purchases in 2006.